Available datapackage for study 'A Dose Finding Study of GSK716155 Versus Placebo in the Treatment of Type 2 Diabetes Mellitus'

GlaxoSmithKline

Description

This is a randomized, double-blind, placebo-controlled, multicenter, 4-parallel-group, dose ranging study evaluating the dose response, efficacy and safety of subcutaneously injected GSK716155 (albiglutide) in Japanese subjects with type 2 diabetes mellitus.

Citations (0)

Mentions (0)

Metrics

Dataset Index

0.2

FAIR Score

31%

Citations

0

Mentions

0

Metrics Over Time

Publication Details

DOI

Publisher

Vivli

License

Study data may be accessed by completing a request form at https://vivli.org. It will then be reviewed according to the data contributor’s governance policy, see https://vivli.org/members/ourmembers/ for Vivli member’s review process. If approved, use of the data is governed by the data use agreement at https://vivli.org/resources/vivli-data-use-agreement/

Assigned Domain

Subfield

Pharmacology

Field

Medicine

Domain

Health Sciences

Confidence Score

50%

Source

Scholar Data Model

Keywords

Conditions: Diabetes Mellitus, Type 2Interventions: albiglutideInterventions: placebo

Normalization Factors

FT

51.92

CTw

1.00

MTw

1.00